读取中,请稍候

00-00 00:00:00
--.--
0.00 (0.000%)
昨收盘:0.000今开盘:0.000最高价:0.000最低价:0.000
成交额:0成交量:0买入价:0.000卖出价:0.000
市盈率:0.000收益率:0.00052周最高:0.00052周最低:0.000
一致B:2021年第一季度报告全文(英文版) 下载公告
公告日期:2021-04-24

ChinaNationalAccordMedicinesCorporationLtd.

FirstQuarterlyReport2021

April2021

SectionI.ImportantNotesBoardofDirectorsandtheSupervisoryCommitteeofChinaNationalAccordMedicinesCorporationLtd.(hereinafterreferredtoastheCompany)anditsdirectors,supervisorsandseniorexecutivesshouldguaranteethereality,accuracyandcompletionofthequarterlyreport,therearenoanyfictitiousstatements,misleadingstatementsorimportantomissionscarriedinthisreport,andshalltakelegalresponsibilities,individualand/orjoint.AllDirectorsareattendedtheBoardMeetingforQuarterlyReportdeliberation.LinZhaoxiongpersoninchargeoftheCompany,GuGuolin,personinchargerofaccountingworksandWangYing,personinchargerofaccountingorgan(accountingofficer)herebyconfirmthattheFinancialReportofthisQuarterlyReportisauthentic,accurateandcomplete.

SectionII.Companyprofile

I.MainaccountingdataandfinancialindexesWhetherithasretroactiveadjustmentorre-statementonpreviousaccountingdata

□Yes√No

CurrentPeriodSameperiodoflastyearChangesofthisperiodoversameperiodoflastyear
Operatingincome(RMB)16,049,966,325.7512,824,196,278.6625.15%
NetprofitattributabletoshareholdersofthelistedCompany(RMB)328,800,560.24248,800,655.8832.15%
Netprofitattributabletoshareholdersofthelistedcompanyafterdeductingnon-recurringgainsandlosses(RMB)321,593,612.98241,724,850.9533.04%
Netcashflowsfromoperatingactivities(RMB)-306,748,999.24-688,273,848.6355.43%
Basicearningspershare(RMB/Share)0.770.5832.76%
Dilutedearningspershare(RMB/Share)0.770.5832.76%
WeightedaverageROE2.33%1.92%0.41percentagepointup
AttheendofthereportingperiodAttheendoflastyearChangesofthisperiod-endoversameperiod-endoflastyear
Totalassets(RMB)43,020,753,415.9239,594,533,471.658.65%
Netassetsattributabletoshareholderoflistedcompany(RMB)14,277,162,387.0413,948,322,652.332.36%

Itemsofnon-recurringgainsandlosses

√Applicable□Notapplicable

InRMB

ItemAmountfromyear-begintoperiod-endNote
Gains/lossesfromthedisposalofnon-currentasset(includingthewrite-offthataccruedforimpairmentofassets)216,388.08Thegainsofdisposaloftheright-of-useassetsfromstoreleasesurrenderandthelossfromfixedassetsscrapping
Governmentalsubsidyreckonedintocurrentgains/losses(notincludingthesubsidyenjoyedinquotaorrationaccordingtonationalstandards,whicharecloselyrelevanttoenterprise’sbusiness)9,265,003.74VariousspecialsubsidiesandtaxrebatesreceivedinthePeriod
Switchbackofprovisionfordepreciationofaccountreceivableandcontractassetsthatareindividuallytestedforimpairment78,530.15
Othernon-operatingincomeandexpenditureexceptfortheaforementioneditems5,180,996.84Thenon-operatingincomearisingfromwrittenoffthemoneynotrequiredtobepaid
Othergains/lossessatisfyadefinitionofextraordinarygains/losses609,647.62
Less:Impactonincometax3,348,453.94
Impactonminorityshareholders’equity(post-tax)4,795,165.23
Total7,206,947.26--

Concerningtheextraordinaryprofit(gain)/lossdefinedbyQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,andtheitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,explainreasons

□Applicable√NotapplicableInreportingperiod,theCompanyhasnoparticularaboutitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss

II.Totalnumberofshareholdersattheendofthisreportperiodandtoptenshareholders

1.Totalnumberofcommonshareholdersattheendofthisreportperiodandtoptencommonshareholders

Inshares

Totalcommonshareholdersattheendofreportperiod42,431Totalpreferenceshareholderswithvotingrightsrecoveredatendofreportingperiod(ifapplicable)0
Toptenshareholders
Shareholder’snameNatureofshareholderProportionofsharesheldAmountofsharesheldAmountofrestrictedsharesheldNumberofsharepledged/frozen
StateofshareAmount
SinopharmGroupCo.,Ltd.State-ownedlegalperson56.06%239,999,9915,505,770
HongKongSecuritiesClearingCompanyLtdForeignCorporation3.55%15,215,743
FIRSTSENTIERINVESTORSGLOBALUMBRELLAForeignCorporation2.68%11,469,644
FUNDPLC-FSSACHINAGROWTHFUND
ChinaNationalPharmaceuticalForeignTradeCorp.State-ownedlegalperson1.24%5,323,043
NationalSocialSecurityFund-portfolio413Domesticnonstate-ownedCorporation0.97%4,161,032
CentralHuijinInvestmentLtd.State-ownedlegalperson0.89%3,804,400
BBHBOSS/AFIDELITYFD-CHINAFOCUSFDForeignCorporation0.78%3,358,761
CPICFund-ChinaPacificLifeInsuranceCo.,Lt.-participatinginsurance-CPICfundPICCStockRelativeIncome(guaranteedbonus)singleassetmanagementplanDomesticnonstate-ownedCorporation0.66%2,822,801
FidelityInvestmentManagement(HongKong)Limited-Client’sfundForeignCorporation0.54%2,308,237
ChinaConstructionBankCo.,Ltd.-ChinaEuropeValueDiscoveryEquityFundDomesticnonstate-ownedCorporation0.45%1,921,921
Toptenshareholderswithunrestrictedsharesheld
Shareholder’snameAmountofunrestrictedsharesheldTypeofshares
TypeAmount
SinopharmGroupCo.,Ltd.234,494,221RMBordinaryshares234,494,221
HongKongSecuritiesClearingCompanyLtd15,215,743RMBordinaryshares15,215,743
FIRSTSENTIERINVESTORSGLOBALUMBRELLAFUNDPLC-FSSACHINAGROWTHFUND11,469,644Domesticlistedforeignshares11,469,644
ChinaNationalPharmaceuticalForeignTradeCorp.5,323,043RMBordinaryshares5,323,043
NationalSocialSecurityFund-portfolio4134,161,032RMBordinaryshares4,161,032
CentralHuijinInvestmentLtd.3,804,400RMBordinaryshares3,804,400
BBHBOSS/AFIDELITYFD-CHINAFOCUSFD3,358,761Domesticlistedforeignshares3,358,761
CPICFund-ChinaPacificLifeInsuranceCo.,Lt.-participatinginsurance-CPICfundPICCStockRelativeIncome(guaranteedbonus)singleassetmanagementplan2,822,801RMBordinaryshares2,822,801
FidelityInvestmentManagement(HongKong)Limited-Client’sfund2,308,237RMBordinaryshares2,308,237
ChinaConstructionBankCo.,Ltd.-ChinaEuropeValueDiscoveryEquityFund1,921,921RMBordinaryshares1,921,921
ExplanationonassociatedrelationshipamongtheaforesaidshareholdersSinopharmGroupCo.,Ltd.andChinaNationalPharmaceuticalForeignTradeCorporationhavethesameactualcontroller,whichisChinaNationalPharmaceuticalGroupCorporation.ItisunknownthatthereexistsnoassociatedrelationshiporbelongstotheconsistentactionistamongtheothertradableshareholdersregulatedbytheManagementMeasureofInformationDisclosureonChangeofShareholdingforListedCompanies.

Whethertoptencommonshareholdersortoptencommonshareholderswithun-restrictsharesheldhaveabuy-backagreementdealinginreportingperiod

□Yes√NoThetoptencommonshareholdersortoptencommonshareholderswithun-restrictsharesheldoftheCompanyhavenobuy-backagreementdealinginreportingperiod.

2.TotalshareholderswithpreferredstockheldatPeriod-endandsharesheldbytoptenshareholderswithpreferredstockheld

□Applicable√Notapplicable

SectionIII.SignificantEventsI.Particularsaboutmaterialchangesinitemsofmainaccountingstatementandfinancialindexandexplanationsofreasons

√Applicable□Notapplicable

1.Receivablefinancing:adecreaseof973.0057millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof-69.25%,mainlybecausethebankacceptancebilldiscountinthePeriodincreased;

2.Short-termborrowings:anincreaseof2335.6654millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof

144.88%,mainlybecausethesupplychainfinancingincreasedinthePeriod;

3.Employeebenefitspayable:adecreaseof115.9978millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof-32.47%,mainlybecausethesalariesandbonusaccruedinthepreviousyeararepaidinthePeriod;

4.Otherpayables:anincreaseof499.6124millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof31.24%,mainlyduetotheequityconsiderationpayablearisingfromacquisitionofYunnanGuodaDishengDrugstoreChainCo.,LtdandYunnanGuodaDishengPharmacyCo.,ltdbysubsidiaryofthecompany-SinopharmHoldingGuodaDrugstoreCo.,Ltd.(hereinafterreferredtoasGuodaDrugstore),andthefactoringreturnofunrecoverableaccountreceivableincreasedinthePeriod;

5.Financecosts:anincreaseof21.6634millionYuanonayear-on-yearbasis,withagrowthrateof74.67%,mainlybecausepayingalargeamountofequityacquisitionconsiderationin2020,resultinginareductioninbankdeposit,andtheinterestfrombankdepositdeclinedcorrespondingly,andtheinterestexpensesonsupplychainfinancingincreasedonay-o-ybasis;

6.Investmentincome:anincreaseof48.6294millionYuanonayear-on-yearbasis,withagrowthrateof113.95%,mainlybecausetheinvestmentincomefromassociatedenterpriseincreasedfromayearearlier;

7.Impairmentlosses:anincreaseof1.8901millionYuanonayear-on-yearbasis,withagrowthrateof118.24%,mainlybecauseprovisionforfallingpriceofinventoriesincreasedonay-o-ybasis;

8.Gainondisposalofassets:anincreaseof0.5332millionYuanonayear-on-yearbasis,withagrowthrateof204.07%,mainlyduetothegainsofdisposaloftheright-of-useassetsfromretailstoreleasesurrender;

9.Non-operatingincome:anincreaseof4.5591millionYuanonayear-on-yearbasis,withagrowthrateof251.64%,mainlybecausewrittenoffthemoneynotrequiredtobepaidinthePeriod;

10.Non-operatingexpenses:adecreaseof1.1396millionYuanonayear-on-yearbasis,withagrowthrateof-66.63%,mainlybecausetheamercementoutlaydeclinedinthePeriod;

11.Netprofit:anincreaseof94.4755millionYuanonayear-on-yearbasis,withagrowthrateof32.02%,mainlybecauseoperationinthePeriodhasagrowthperformance,soaringoperationincomemakesthegrossprofitincreasedandtheinvestmentincomefromassociatedenterpriseincreasedfromayearearlier;

12.Profitorlossfromcontinuingoperations:anincreaseof94.4755millionYuanonayear-on-yearbasis,withagrowthrateof

32.02%,mainlybecauseoperationinthePeriodhasagrowthperformance,soaringoperationincomemakesthegrossprofitincreasedandtheinvestmentincomefromassociatedenterpriseincreasedfromayearearlier;

13.Netprofitattributabletoownersoftheparentcompany:anincreaseof79.9999millionYuanonayear-on-yearbasis,withagrowthrateof32.15%,mainlybecauseoperationinthePeriodhasagrowthperformance,soaringoperationincomemakesthegrossprofitincreasedandtheinvestmentincomefromassociatedenterpriseincreasedfromayearearlier;

14.Netprofitattributabletonon-controllinginterests:anincreaseof14.4755millionYuanonayear-on-yearbasis,withagrowthrateof31.27%,mainlybecausethesubsidiaryGuodaDrugstore’snetprofitattributabletotheownersoftheparentcompanyincreasedyear-on-year,correspondinglytheminorityshareholder’sgains/lossesattributabletothegroup’sstrategicinvestorWalgreensBootsAlliance(HongKong)InvestmentsLimited(hereinafterreferredtoas"WBA")increased;

15.Othercomprehensiveincome,netoftax:anincreaseof84,503.76Yuanonayear-on-yearbasis,withagrowthrateof100.00%,mainlybecauseothercomprehensiveincomeofassociateschangedduringthecurrentperiod;

16.Othercomprehensiveincomeattributabletoshareholdersofownersoftheparent,netoftax:anincreaseof84,503.76Yuanonayear-on-yearbasis,withagrowthrateof100.00%,mainlybecauseothercomprehensiveincomeofassociateschangedduringthecurrentperiod;

17.Othercomprehensiveincomethatmaybereclassifiedtoprofitorloss:anincreaseof84,503.76Yuanonayear-on-yearbasis,withagrowthrateof100.00%,mainlyduetotheothercomprehensiveincomeavailablefortransfertoprofit/lossarisingfromassociatesinthePeriod;

18.Totalcomprehensiveincome:anincreaseof94.56millionYuanonayear-on-yearbasis,withagrowthrateof32.04%,mainlyduetotherelativelygoodoperatinggrowthinthecurrentperiod,grossprofitincreasedforthesoaringoperationincome,andtheinvestmentincomefromassociatesincreasedonay-o-ybasis;

19.Totalcomprehensiveincomeattributabletoownersoftheparent:anincreaseof80.0844millionYuanonayear-on-yearbasis,withagrowthrateof32.19%,mainlyduetotherelativelygoodoperatinggrowthinthecurrentperiod,grossprofitincreasedforthesoaringoperationincome,andtheinvestmentincomefromassociatesincreasedonay-o-ybasis;

20.Totalcomprehensiveincomeattributabletonon-controllinginterests:anincreaseof14.4755millionYuanonayear-on-yearbasis,withagrowthrateof31.27%,mainlybecausethenetprofitattributabletoownersofparentcompanyfromsubsidiaryGuodaDrugstorehasanincreasedfromayearearlier,andcorrespondinglytheminorityshareholder’sgains/lossesattributabletothegroup’sstrategicinvestorWBAincreased;

21.Basicearningspershare:anincreaseof0.19Yuan/shareonayear-on-yearbasis,withagrowthrateof32.76%,mainlyduetotherelativelygoodoperatinggrowthinthecurrentperiod,grossprofitincreasedforthesoaringoperationincome,andtheinvestmentincomefromassociatesincreasedonay-o-ybasis,therefore,thenetprofitattributabletoshareholdersoflistedcompanyincreased

32.15%fromayearearlier,basicEPSgrowthcorrespondinglywith32.76%up;

22.Dilutedearningspershare:anincreaseof0.19Yuan/shareonayear-on-yearbasis,withagrowthrateof32.76%,mainlyduetotherelativelygoodoperatinggrowthinthecurrentperiod,grossprofitincreasedforthesoaringoperationincome,andtheinvestmentincomefromassociatesincreasedonay-o-ybasis,therefore,thenetprofitattributabletoshareholdersoflistedcompanyincreased

32.15%fromayearearlier,dilutedEPSgrowthcorrespondinglywith32.76%up;

23.Receiptsoftaxesandsurchargesrefunds:anincreaseof4.8427millionYuanonayear-on-yearbasis,withagrowthrateof

624.66%,mainlyduetothereceiptofoverpaidcorporateincometaxrebatesinpreviousyears;

24.Othercashreceiptsrelatingtooperatingactivities:adecreaseof223.6696millionYuanonayear-on-yearbasis,withagrowthrateof-51.61%,mainlyduetotheyear-on-yeardecreaseinspecialreservefundsreceivedinthisperiod;

25.Netcashflowsfromoperatingactivities:anincreaseof381.5248millionYuanonayear-on-yearbasis,withagrowthrateof

55.43%,mainlyduetotheincreaseinoperatingincome,thecashreceivedfromthesaleofgoodsandtheprovisionoflaborservicesincreasedaccordingly;

26.Cashreceiptsfromreturnsofinvestments:anincreaseof2.9974millionYuanonayear-on-yearbasis,withagrowthrateof

100.00%,mainlybecausethecompanyreceivedthewithdrawalfundsfromtheSinopharmZhongjinMedicalIndustryFundinvestmentprojectintheperiod,andtherewasnosuchmatterinthesameperiodlastyear;

27.Cashreceivedfromreturnsoninvestments:anincreaseof3.5996millionYuanonayear-on-yearbasis,withagrowthrateof

100.00%,mainlybecausethecompanyreceiveddividendsfromSinopharmZhongjinMedicalIndustryFundprojectinvestmentintheperiod,andtherewasnosuchmatterinthesameperiodlastyear;

28.Netcashreceiptsfromdisposaloffixedassets,intangibleassetsandotherlong-termassets:anincreaseof0.2197millionYuanonayear-on-yearbasis,withagrowthrateof204.49%,mainlyduetothecashreceivedfromthedisposaloffixedassetsincreasedintheperiod;

29.Othercashreceiptsrelatingtoinvestingactivities:adecreaseof22millionYuanonayear-on-yearbasis,withagrowthrateof-100.00%,mainlybecauseatsameperiodlastyear,thePudongNewAreaofShanghaiPharmaceuticalMedicineLtdwascombinedunderthesamecontrolbythesubsidiaryofthecompany-GuodaDrugstore,andrecoveryofthebalanceoriginallycollectedinthe

cashpoolofitsoriginalparentcompany,whiletherewasnosuchmatterinthecurrentperiod;

30.Totalcashinflowsfrominvestingactivities:adecreaseof15.1833millionYuanonayear-on-yearbasis,withagrowthrateof-68.68%,mainlybecauseatsameperiodlastyear,thePudongNewAreaofShanghaiPharmaceuticalMedicineLtdwascombinedunderthesamecontrolbythesubsidiaryofthecompany-GuodaDrugstore,andrecoveryofthebalanceoriginallycollectedinthecashpoolofitsoriginalparentcompany,whiletherewasnosuchmatterinthecurrentperiod;

31.Cashpaymentsforinvestments:anincreaseof15.7387millionYuanonayear-on-yearbasis,withagrowthrateof138.78%,mainlyduetotheyear-on-yearincreaseinthepaymentofstoreredemptionfeesbyGuodaDrugstore,asubsidiaryofthecompany;

32.Netcashpaymentsforacquisitionofsubsidiariesandotherbusinessunits:adecreaseof591.7232millionYuanonayear-on-yearbasis,withagrowthrateof-89.00%,mainlybecausepaymentfortheacquisitionofthesubsidiaryfromGuodaDrugstoreinthecurrentperiodhasdecreasedcomparedwiththesameperiodlastyear;

33.Othercashpaymentsrelatingtoinvestingactivities:adecreaseof41.3645millionYuanonayear-on-yearbasis,withagrowthrateof-100.00%,mainlybecausethepaymentofequityacquisitionforpreviousyearhasbeenpaidatsameperiodlastyear,whiletherewasnosuchmatterinthisperiod;

34.Totalcashoutflowsfrominvestingactivities:adecreaseof605.5959millionYuanonayear-on-yearbasis,withagrowthrateof-78.87%,mainlybecausepaymentfortheacquisitionofthesubsidiaryfromGuodaDrugstoreinthecurrentperiodhasdecreasedcomparedwiththesameperiodlastyear;

35.Netcashflowfrominvestmentactivities:anincreaseof590.4126millionYuanonayear-on-yearbasis,withagrowthrateof

79.18%,mainlybecausepaymentfortheacquisitionofthesubsidiaryfromGuodaDrugstoreinthecurrentperiodhasdecreasedcomparedwiththesameperiodlastyear;

36.Cashproceedsfrominvestmentsbyothers:anincreaseof5.88millionYuanonayear-on-yearbasis,withagrowthrateof

100.00%,mainlyduetothereceiptofinvestmentfundsfromminorityshareholdersinthisperiod,whiletherewasnosuchmatterinthesameperiodlastyear;

37.Cashreceivedfromborrowing:anincreaseof281.1937millionYuanonayear-on-yearbasis,withagrowthrateof98.25%,mainlybecausethebankloansreceivedduringthecurrentperiodincreased;

38.Totalcashinflowsfromfinancingactivities:anincreaseof247.4363millionYuanonayear-on-yearbasis,withagrowthrateof

39.70%,mainlybecausethebankloansreceivedduringthecurrentperiodincreased;

39.Othercashpaymentsrelatingtofinancingactivities:adecreaseof227.8233millionYuanonayear-on-yearbasis,withagrowthrateof-48.10%,mainlyduetotheinvestmentamountpaidformergerthePudongNewAreaofShanghaiPharmaceuticalMedicineLtdunderthesamecontrolbythesubsidiaryofthecompany-GuodaDrugstoreatsameperiodlastyear,whiletherewasnosuchmatterinthecurrentperiod;

40.Netcashflowsfromfinancingactivities:anincreaseof445.6404millionYuanonayear-on-yearbasis,withagrowthrateof

780.23%,mainlybecausebankloansreceivedinthePeriodincreasedandatsameperiodlastyear,theinvestmentamountarepaidforcombinedthePudongNewAreaofShanghaiPharmaceuticalMedicineLtdunderthesamecontrolbyGuodaDrugstore,therewasnosuchmatterinthecurrentperiod;

41.Effectofexchangeratechangesoncashandcashequivalents:adecreaseof2,805.98Yuanonayear-on-yearbasis,withagrowthrateof-768.34%,mainlyduetotheimpactofexchangeratechanges;

42.Netincreaseincashandcashequivalents:anincreaseof1,417.5751millionYuanonayear-on-yearbasis,withagrowthrateof

95.07%,mainlyduetotheincreaseinoperatingincome,thecashreceivedfromthesaleofgoodsandtheprovisionoflaborservicesincreasedaccordingly;andthepaymentforsubsidiaryacquisitionfromsubsidiaryGuodaDrugstoredeclinedfromayearearlier.

43.Cashandcashequivalentsatbeginningoftheyear:adecreaseof3,020.9579millionYuanonayear-on-yearbasis,withagrowthrateof-35.85%,mainlybecausethecompanypaidalargeamountofequitypurchaseconsiderationin2020,resultinginadecreaseinthebalanceofcashandcashequivalentsatthebeginningoftheyear.

II.Analysisandexplanationofsignificanteventsandtheirinfluenceandsolutions

□Applicable√NotapplicableProgressofsharesbuy-back

□Applicable√NotapplicableImplementationprogressofthereductionofrepurchasessharesbycentralizedbidding

□Applicable√Notapplicable

III.CommitmentscompletedinPeriodandthosewithoutcompletedtillendofthePeriodfromactualcontroller,shareholders,relatedparties,purchaserandcompanies

□Applicable√NotapplicableTheCompanyhasnocommitmentscompletedinPeriodandthosewithoutcompletedtillendofthePeriodfromactualcontroller,shareholders,relatedparties,purchaserandcompanies.IV.Financialassetinvestment

1.Securitiesinvestment

□Applicable√NotapplicableNosecurityinvestmentinthePeriod.

2.Derivativeinvestment

□Applicable√NotapplicableNoderivativeinvestmentinthePeriod.V.Progressofinvestmentprojectswithraisedfunds

□Applicable√Notapplicable

VI.PredictionofbusinessperformancefromJanuary–June2021Estimationonaccumulativenetprofitfromthebeginningoftheyeartotheendofnextreportperiodtobelossprobablyorthewarningofitsmaterialchangecomparedwiththecorrespondingperiodofthelastyearandexplanationonreason

□Applicable√NotapplicableVII.Majorcontractsfordailyoperations

□Applicable√NotapplicableVIII.Trustfinancing

□Applicable√Notapplicable

NotrustfinancinginthePeriod.

IX.Guaranteeoutsideagainsttheregulation

□Applicable√NotapplicableTheCompanyhadnoguaranteeoutsideagainsttheregulationintheperiod.

X.Non-operationalfundoccupationfromcontrollingshareholdersanditsrelatedparty

□Applicable√NotapplicableTheCompanyhadnonon-operationalfundoccupationformcontrollingshareholdersanditsrelatedpartyintheperiod.

XI.Registrationformforreceivingresearch,communicationandinterviewinthereportperiod

□Applicable√NotapplicableTheCompanyhadnoreceivingresearch,communicationorinterviewinthereportperiod.

SectionIV.FinancialStatementI.FinancialStatement

1.ConsolidateBalanceSheet

PreparedbyChinaNationalAccordMedicinesCorporationLtd.

March31,2021

InRMB

ItemMarch31,2021December31,2020
Currentassets:
Cashandbankbalances5,840,135,730.115,998,204,295.87
Settlementprovisions
Capitallent
Tradingfinancialassets
Derivativefinancialassets
Notesreceivable607,883,873.14622,115,477.04
Accountsreceivable16,780,830,492.0313,799,971,014.22
Receivablefinancing431,981,996.921,404,987,700.38
Advancestosuppliers590,101,876.56480,313,574.71
Insurancereceivable
Reinsurancereceivables
Contractreserveofreinsurancereceivable
Otherreceivables628,399,715.32535,228,747.69
Including:Interestreceivable
Dividendreceivable
Buyingbackthesaleoffinancialassets
Inventories7,219,060,669.896,285,010,674.46
Contractassets15,417,457.5015,177,731.64
Assetsheldforsale
Non-currentassetduewithinoneyear
Othercurrentassets123,484,117.46121,082,863.45
Totalcurrentassets32,237,295,928.9329,262,092,079.46
Non-currentassets:
Loansandpaymentsonbehalf
Debtinvestment
Otherdebtinvestment
Long-termaccountreceivable
Long-termequityinvestment2,379,500,628.902,287,019,627.99
Otherequityinstrumentinvestment99,488,340.2899,488,340.28
Othernon-currentfinancialassets117,974,908.51120,972,350.24
Investmentproperties125,907,819.38127,444,379.94
Fixedassets843,319,270.30854,191,083.27
Constructioninprogress49,119,148.8946,631,190.23
Productivebiologicalasset
Oilandgasasset
Right-of-useassets2,410,848,611.312,356,952,392.99
Intangibleassets722,392,930.27734,345,179.40
ExpenseonResearchandDevelopment
Goodwill2,975,269,022.112,747,375,281.11
Long-termprepaidexpenses489,002,945.70457,705,276.09
Deferredtaxassets97,737,555.4192,118,767.81
Othernon-currentasset472,896,305.93408,197,522.84
Totalnon-currentasset10,783,457,486.9910,332,441,392.19
Totalassets43,020,753,415.9239,594,533,471.65
Currentliabilities:
Short-termborrowings3,947,852,429.691,612,187,020.12
Loanfromcentralbank
Capitalborrowed
Tradingfinancialliability
Derivativefinancialliability
Notespayable6,411,005,653.207,520,165,274.69
Accountspayable9,161,357,988.537,697,451,142.50
Receiptsinadvance10,089,304.6112,352,466.64
Contractliabilities382,788,595.61368,600,357.14
Sellingfinancialassetofrepurchase
Absorbingdepositandinterbankdeposit
Securitytradingofagency
Securitysalesofagency
Employeebenefitspayable241,214,266.47357,212,047.10
Taxpayable262,688,620.52316,867,149.16
Otherpayables2,098,779,260.441,599,166,881.14
Including:Interestpayable25,916,885.6435,572,620.82
Dividendpayable6,389,320.966,389,320.96
Commissionchargeandcommissionpayable
Reinsurancepayable
Liabilityheldforsale
Non-currentliabilitiesduewithinoneyear767,942,185.69748,732,059.89
Othercurrentliabilities27,334,439.9724,787,078.55
Totalcurrentliabilities23,311,052,744.7320,257,521,476.93
Non-currentliabilities:
Insurancecontractreserve
Long-termborrowings31,637,173.8931,637,173.89
Bondspayable
Including:Preferredstock
Perpetualcapitalsecurities
Leaseliabilities1,304,731,241.221,303,054,163.90
Long-termpayables6,938,189.006,938,189.00
Long-termemployeebenefitspayable1,319,000.001,319,000.00
Provisions68,808,166.7968,808,166.79
Deferredincome94,199,523.3389,843,583.37
Deferredtaxliabilities201,334,176.46205,921,408.66
Othernon-currentliabilities675,330,586.26740,862,989.59
Totalnon-currentliabilities2,384,298,056.952,448,384,675.20
Totalliabilities25,695,350,801.6822,705,906,152.13
Owner’sequity:
Sharecapital428,126,983.00428,126,983.00
Otherequityinstrument
Including:Preferredstock
Perpetualcapitalsecurities
Capitalsurplus4,372,458,724.434,372,504,053.72
Less:Inventoryshares
Othercomprehensiveincome38,567,521.4838,483,017.72
Reasonablereserve
Surplusreserve214,063,491.50214,063,491.50
Provisionofgeneralrisk
Retainedearnings9,223,945,666.638,895,145,106.39
Totalequityattributabletoownersoftheparent14,277,162,387.0413,948,322,652.33
Non-controllinginterests3,048,240,227.202,940,304,667.19
Totalequity17,325,402,614.2416,888,627,319.52
Totalliabilitiesandequity43,020,753,415.9239,594,533,471.65

LegalRepresentative:LinZhaoxiongPersoninchargeofaccountingworks:GuGuolinPersoninchargeofaccountinginstitute:WangYing

2.BalanceSheetofParentCompany

InRMB

ItemMarch31,2021December31,2020
Currentassets:
Cashandbankbalances2,918,160,838.333,020,909,473.71
Tradingfinancialassets
Derivativefinancialassets
Notesreceivable27,981,836.4730,984,449.44
Accountsreceivable682,802,750.34609,575,301.13
Receivablesfinancing18,049,841.4330,248,631.32
Advancestosuppliers3,878,976.706,722,204.59
Otherreceivables3,762,424,972.633,562,309,346.07
Including:Interestreceivable
Dividendreceivable
Inventories217,381,506.64172,275,777.63
Contractassets127,994.54139,154.54
Assetsheldforsale
Non-currentassetsmaturingwithinoneyear
Othercurrentassets39,482.3839,482.38
Totalcurrentassets7,630,848,199.467,433,203,820.81
Non-currentassets:
Debtinvestment
Otherdebtinvestment
Long-termreceivables
Long-termequityinvestments7,965,880,218.997,873,668,245.16
Investmentinotherequityinstrument
Othernon-currentfinancialassets117,974,908.51120,972,350.24
Investmentproperties1,444,115.411,452,132.04
Fixedassets12,387,613.2313,279,902.76
Constructioninprogress
Productivebiologicalassets
Oilandnaturalgasassets
Right-of-useassets4,863,467.725,142,755.88
Intangibleassets4,687,410.114,622,268.00
Researchanddevelopmentcosts
Goodwill
Long-termdeferredexpenses4,102,834.804,335,802.92
Deferredtaxassets9,218,485.219,025,057.52
Othernon-currentassets12,304,025.2112,967,715.50
Totalnon-currentassets8,132,863,079.198,045,466,230.02
Totalassets15,763,711,278.6515,478,670,050.83
Currentliabilities
Short-termborrowings739,174,743.69157,892,942.24
Tradingfinancialliability
Derivativefinancialliability
Notespayable295,146,453.96756,364,719.49
Accountspayable417,332,303.36407,275,713.49
Accountsreceivedinadvance
Contractliabilities8,613,252.721,807,562.61
Employeebenefitspayable25,041,540.0436,672,344.48
Taxpayables17,831,732.4313,975,905.04
Otherpayables3,204,307,483.053,167,152,583.28
Including:Interestpayable217,961.01170,214.19
Dividendpayable
Liabilityheldforsale
Non-currentliabilitiesduewithinoneyear1,067,368.381,056,120.58
Othercurrentliabilities1,484,550.54636,200.63
Totalcurrentliabilities4,709,999,428.174,542,834,091.84
Non-currentliabilities:
Long-termborrowings31,637,173.8931,637,173.89
Bondspayable
Including:preferredstock
Perpetualcapitalsecurities
Leaseliabilities4,184,170.004,455,967.97
Long-termpayables800,000.00800,000.00
Longtermemployeecompensationpayable
Accruedliabilities
Deferredincome715,398.06827,658.18
Deferredincometaxliabilities
Othernon-currentliabilities10,538.5811,042.52
Totalnon-currentliabilities37,347,280.5337,731,842.56
Totalliabilities4,747,346,708.704,580,565,934.40
Owners’equity:
Sharecapital428,126,983.00428,126,983.00
Otherequityinstrument
Including:preferredstock
Perpetualcapitalsecurities
Capitalsurplus4,467,946,102.304,467,991,431.59
Less:Inventoryshares
Othercomprehensiveincome-43,529.56-128,033.32
Specialreserve
Surplusreserve214,063,491.50214,063,491.50
Retainedearnings5,906,271,522.715,788,050,243.66
Totalshareholders’equity11,016,364,569.9510,898,104,116.43
Totalliabilitiesandshareholders’equity15,763,711,278.6515,478,670,050.83

3.ConsolidatedProfitStatement

InRMB

ItemCurrentperiodLastperiod
I.Totaloperatingincome16,049,966,325.7512,824,196,278.66
Including:Operatingrevenue16,049,966,325.7512,824,196,278.66
Interestincome
Insurancegained
Commissionchargeandcommissionincome
II.Totaloperatingcost15,663,170,079.6012,488,521,944.35
Including:Operatingcost14,260,591,404.4611,370,970,742.96
Interestexpense
Commissionchargeandcommissionexpense
Cashsurrendervalue
Netamountofexpenseofcompensation
Netamountofwithdrawalofinsurancecontractreserve
Bonusexpenseofguaranteeslip
Reinsuranceexpense
Taxandsurcharges33,744,327.2029,109,421.79
Sellingexpenses1,080,543,941.75844,624,826.78
Administrativeexpense237,615,927.36214,805,866.61
R&Dexpense
Financecosts50,674,478.8329,011,086.21
Including:Interestexpense68,683,688.4960,067,901.98
Interestincome18,058,735.0329,094,889.11
Add:otherincome13,655,624.7213,133,111.50
Investmentincome(Lossislistedwith“-”)91,305,476.7442,676,071.54
Including:Investmentincomefromassociates92,441,826.4460,020,272.13
Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcost(Lossislistedwith“-”)-4,735,905.31-18,342,866.43
Exchangeincome(Lossislistedwith“-”)
Netexposurehedgingincome(Lossislistedwith“-”)
Incomefromchangeoffairvalue(Lossislistedwith“-”)
Creditimpairmentlosses(Lossislistedwith“-”)-17,197,080.80-16,845,052.13
Impairmentlosses(Lossislistedwith“-”)-3,488,500.85-1,598,436.71
Gainondisposalofassets(Lossislistedwith“-”)271,889.26-261,264.83
III.Operatingprofit(Lossislistedwith“-”)471,343,655.22372,778,763.68
Add:Non-operatingincome6,370,834.891,811,729.05
Less:Non-operatingexpense570,737.091,710,329.13
IV.Totalprofit477,143,753.02372,880,163.60
Less:Incometaxexpense87,580,022.0077,791,885.48
V.Netprofit(Netlossislistedwith“-”)389,563,731.02295,088,278.12
(i)Classifybybusinesscontinuity
1.Profitorlossfromcontinuingoperations389,563,731.02295,088,278.12
2.terminationofnetprofit(netlosslistedwith‘-”)
(ii)Classifybyownership
1.Netprofitattributabletoownersoftheparent328,800,560.24248,800,655.88
2.Non-controllinginterests60,763,170.7846,287,622.24
VI.Othercomprehensiveincome,netoftax84,503.76
Othercomprehensiveincomeattributabletoshareholdersofownersoftheparent,netoftax84,503.76
(i)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss
1.Changesofthedefinedbenefitplansthatre-measured
2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss
3.Changeoffairvalueofinvestmentinotherequityinstrument
4.Fairvaluechangeofenterprise'screditrisk
5.Other
(ii)Othercomprehensiveincomethatmaybereclassifiedtoprofitorloss84,503.76
1.Othercomprehensiveincomeusingtheequitymethodthatmaybereclassifiedtoprofitorloss84,503.76
2.Changeoffairvalueofotherdebtinvestment
3.Amountoffinancialassetsre-classifytoothercomprehensiveincome
4.Creditimpairmentprovisionforotherdebtinvestment
5.Cashflowhedgingreserve
6.Translationdifferencesarisingontranslationofforeigncurrency
financialstatements
7.Other
Netafter-taxofothercomprehensiveincomeattributabletominorityshareholders
VII.Totalcomprehensiveincome389,648,234.78295,088,278.12
Totalcomprehensiveincomeattributabletoownersoftheparent328,885,064.00248,800,655.88
Totalcomprehensiveincomeattributabletonon-controllinginterests60,763,170.7846,287,622.24
VIII.Earningspershare:
(i)Basicearningspershare0.770.58
(ii)Dilutedearningspershare0.770.58

EnterprisecombineunderthesamecontrolinthePeriod,thecombinedpartyrealizednetprofitof0Yuanbeforecombination,andrealized0YuanatlastperiodforcombinedpartyLegalRepresentative:LinZhaoxiongPersoninchargeofaccountingworks:GuGuolinPersoninchargeofaccountinginstitute:WangYing

4.ProfitStatementofParentCompany

InRMB

ItemCurrentperiodLastperiod
I.Operatingrevenue1,031,796,119.30883,090,683.07
Less:Operatingcosts991,971,454.23850,760,365.77
Taxesandsurcharge1,161,587.511,011,193.50
Sellingexpenses16,856,699.3516,302,891.84
Administrativeexpenses20,817,040.6222,374,408.72
R&Dexpenses
Financecosts-29,303,964.67-22,842,676.94
Including:interestexpense10,689,978.609,151,290.82
Interestincome40,183,409.9432,061,791.21
Add:otherincome401,103.90293,056.51
Investmentincome(Lossislistedwith“-”)95,583,979.8860,592,685.27
Including:InvestmentincomeonaffiliatedCompanyandjointventure92,172,799.3660,134,457.45
Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcost(Lossislistedwith“-”)-188,375.09-540,438.02
Netexposurehedgingincome(Lossislistedwith“-”)
Changingincomeoffairvalue(Lossislistedwith“-”)
Creditimpairmentlosses(Lossislistedwith“-”)-973,888.89
Impairmentlosses(Lossislistedwith“-”)-561,173.91217,422.14
Gainondisposalofassets(Lossislistedwith“-”)22,815.68
II.Operatingprofit(Lossislistedwith“-”)125,740,027.8175,613,775.21
Add:Non-operatingincome1,645.981,578.11
Less:Non-operatingexpense
III.TotalProfit(Lossislistedwith“-”)125,741,673.7975,615,353.32
Less:Incometaxexpense7,520,394.743,620,557.51
IV.Netprofit(Netlossislistedwith“-”)118,221,279.0571,994,795.81
(i)Profitorlossfromcontinuingoperations(netlosslistedwith‘-”)118,221,279.0571,994,795.81
(ii)terminationofnetprofit(netlosslistedwith‘-”)
V.Othercomprehensiveincome,netoftax84,503.76
(i)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss
1.Changesofthedefinedbenefitplansthatre-measured
2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss
3.Changeoffairvalueofinvestmentinotherequityinstrument
4.Fairvaluechangeofenterprise'screditrisk
5.Other
(ii)Othercomprehensiveincomethatmaybereclassifiedtoprofitorloss84,503.76
1.Othercomprehensiveincomeusingtheequitymethodthatmaybereclassifiedtoprofitorloss84,503.76
2.Changeoffairvalueofotherdebtinvestment
3.Amountoffinancialassetsre-classifytoothercomprehensiveincome
4.Creditimpairmentprovisionforotherdebtinvestment
5.Cashflowhedgingreserve
6.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements
7.Other
VI.Totalcomprehensiveincome118,305,782.8171,994,795.81
VII.Earningspershare:
(i)Basicearningspershare
(ii)Dilutedearningspershare

5.ConsolidatedCashFlowStatement

InRMB

ItemCurrentperiodLastperiod
I.Cashflowsfromoperatingactivities:
Cashreceivedfromsalesofgoodorrenderingofservices15,194,724,502.1213,201,992,638.81
Netincreaseofcustomerdepositandinterbankdeposit
Netincreaseofloanfromcentral
bank
Netincreaseofcapitalborrowedfromotherfinancialinstitution
Cashreceivedfromoriginalinsurancecontractfee
Netcashreceivedfromreinsurancebusiness
Netincreaseofinsuredsavingsandinvestment
Cashreceivedfrominterest,commissionchargeandcommission
Netincreaseofcapitalborrowed
Netincreaseofreturnedbusinesscapital
Netcashreceivedbyagentsinsaleandpurchaseofsecurities
Receiptsoftaxesandsurchargesrefunds5,617,976.11775,261.38
Othercashreceiptsrelatingtooperatingactivities209,745,502.46433,415,062.71
Totalcashinflowsfromoperatingactivities15,410,087,980.6913,636,182,962.90
Cashpaymentsforgoodsandservices14,094,028,880.6512,827,089,312.11
Netincreaseofcustomerloansandadvances
Netincreaseofdepositsincentralbankandinterbank
Cashpaidfororiginalinsurancecontractcompensation
Netincreaseofcapitallent
Cashpaidforinterest,commissionchargeandcommission
Cashpaidforbonusofguaranteeslip
Cashpaymentstoandonbehalfofemployees894,497,321.19703,922,606.95
Paymentsofalltypesoftaxesand354,054,737.85368,976,475.15
surcharges
Othercashpaymentsrelatingtooperatingactivities374,256,040.24424,468,417.32
Totalcashoutflowsfromoperatingactivities15,716,836,979.9314,324,456,811.53
Netcashflowsfromoperatingactivities-306,748,999.24-688,273,848.63
II.Cashflowsfrominvestingactivities:
Cashreceiptsfromreturnsofinvestments2,997,441.73
Cashreceivedfromreturnsoninvestments3,599,555.61
Netcashreceiptsfromdisposaloffixedassets,intangibleassetsandotherlong-termassets327,119.50107,430.91
Netcashreceivedfromdisposalofsubsidiariesandotherunits
Othercashreceiptsrelatingtoinvestingactivities22,000,000.00
Totalcashinflowsfrominvestingactivities6,924,116.8422,107,430.91
Cashpaymentstoacquirefixedassets,intangibleassetsandotherlong-termassets61,960,648.9850,207,587.50
Cashpaymentsforinvestments27,079,733.0011,341,032.15
Netincreaseofmortgagedloans
Netcashpaymentsforacquisitionofsubsidiariesandotherbusinessunits73,159,498.29664,882,681.20
Othercashpaymentsrelatingtoinvestingactivities41,364,521.11
Totalcashoutflowsfrominvestingactivities162,199,880.27767,795,821.96
Netcashflowsfrominvestingactivities-155,275,763.43-745,688,391.05
III.Cashflowsfromfinancingactivities
Cashproceedsfrominvestmentsbyothers5,880,000.00
Incl:Cashreceiptsfromcapitalcontributionsfromnon-controllinginterestsofsubsidiaries5,880,000.00
Cashreceiptsfromborrowings567,395,696.23286,202,002.73
Othercashreceiptsrelatingtofinancingactivities297,416,755.19337,054,182.02
Totalcashinflowsfromfinancingactivities870,692,451.42623,256,184.75
Cashrepaymentsfordebts177,254,802.73142,100,000.00
Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses59,139,307.6664,675,017.27
Incl:Dividendsorprofitpaidtonon-controllingshareholdersofsubsidiaries555,825.801,558,470.71
Othercashpaymentsrelatingtofinancingactivities245,774,326.14473,597,592.59
Totalcashoutflowsfromfinancingactivities482,168,436.53680,372,609.86
Netcashflowsfromfinancingactivities388,524,014.89-57,116,425.11
IV.Effectofforeignexchangeratechangesoncashandcashequivalents-2,440.78365.20
V.Netincreaseofcashandcashequivalents-73,503,188.56-1,491,078,299.59
Add:Cashandcashequivalentsatbeginningoftheyear5,405,113,257.998,426,071,170.16
VI.Cashandcashequivalentsatendofyear5,331,610,069.436,934,992,870.57

6.CashFlowStatementofParentCompany

InRMB

ItemCurrentperiodLastperiod
I.Cashflowsfromoperatingactivities:
Cashreceiptsfromthesaleofgoodsandtherenderingofservices1,022,932,449.001,062,518,589.11
Write-backoftaxreceived
Othercashreceiptsrelatingtooperatingactivities14,576,152.9322,736,474.18
Totalcashinflowsfromoperatingactivities1,037,508,601.931,085,255,063.29
Cashpaymentsforgoodsandservices1,132,644,884.961,207,589,273.35
Cashpaymentstoandonbehalfofemployees41,055,249.9139,968,369.74
Paymentsofalltypesoftaxesandsurcharges12,594,584.8520,509,993.91
Othercashpaymentsrelatingtooperatingactivities5,207,747.5414,820,413.79
Totalcashoutflowsfromoperatingactivities1,191,502,467.261,282,888,050.79
Netcashflowsfromoperatingactivities-153,993,865.33-197,632,987.50
II.Cashflowsfrominvestingactivities:
Cashreceiptsfromreturnsofinvestments2,997,441.7313,636,447.00
Cashreceiptsfromreturnsoninvestments3,599,555.61
Netcashreceiptsfromdisposaloffixedassets,intangibleassetsandotherlong-termassets233,663.00
Netcashreceivedfromdisposalofsubsidiariesandotherunits
Othercashreceiptsrelatingtoinvestingactivities721,955,173.97602,709,245.48
Totalcashinflowsfrominvestingactivities728,785,834.31616,345,692.48
Cashpaidforacquisitionoffixedassets,intangibleassetsandotherlong-termassets710,954.22670,760.44
Cashpaidforinvestment
Netcashreceivedfromsubsidiariesandotherunitsobtained
Othercashpaymentsrelatingtoinvestingactivities895,600,000.00792,214,521.11
Totalcashoutflowsfrominvestingactivities896,310,954.22792,885,281.55
Netcashflowsfrominvestingactivities-167,525,119.91-176,539,589.07
III.Cashflowsfromfinancingactivities
Cashreceivedfromabsorbing
investment
Cashreceiptsfromborrowings210,000,000.0024,694,789.52
Othercashreceiptsrelatingtofinancingactivities8,801,174,486.168,004,663,212.88
Totalcashinflowsfromfinancingactivities9,011,174,486.168,029,358,002.40
Cashrepaymentsfordebts22,594,789.5212,100,000.00
Cashpaymentsfordistributionofdividends,profitorinterestexpenses10,931,189.669,363,675.10
Othercashpaymentsrelatingtofinancingactivities8,758,875,716.347,724,025,779.65
Totalcashoutflowsfromfinancingactivities8,792,401,695.527,745,489,454.75
Netcashflowsfromfinancingactivities218,772,790.64283,868,547.65
IV.Effectofforeignexchangeratechangesoncashandcashequivalents-2,440.78365.20
V.Netincreaseofcashandcashequivalents-102,748,635.38-90,303,663.72
Add:Cashandcashequivalentsatbeginningoftheyear3,020,909,473.712,894,333,956.38
VI.Cashandcashequivalentsatendofyear2,918,160,838.332,804,030,292.66

II.Explanationonfinancialstatementadjustment

1.Financialstatementadjustmentatthebeginningofthefirstyearwhenimplementationofnewleasingrulesfrom2021

□Applicable√Notapplicable

2.Retrospectiveadjustmentofthecomparativedataforinitialnewleasingrulesfrom2021

□Applicable√Notapplicable

III.Auditreport

Whetherthe1

stquarterlyreporthasbeenauditedornot

□Yes√No1QreportoftheCompanyisunaudited.

ChinaNationalAccordMedicinesCorporationLtd.

LegalRepresentative:LinZhaoxiong

24April2021


  附件:公告原文
返回页顶